Foghorn Therapeutics Inc.
FHTXNASDAQHealthcare● Active
$3.84
+$0.13(+3.50%)
Market Cap$225461376
P/E Ratio—
52W High$6.95
52W Low$3.27
Foghorn Therapeutics Inc. (FHTX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FHTX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($74.28M) | ($86.62M) | ($98.43M) | ($108.88M) | ($101.32M) |
| Depreciation & Amort. | $3.33M | $3.12M | $3.45M | $7.90M | $3.23M |
| Stock-Based Comp. | $10.40M | $11.89M | $16.19M | $0.00M | $8.38M |
| Change in Working Capital | ($32.14M) | ($32.27M) | ($41.88M) | $281.55M | $33.44M |
| Net Cash from Operations | ($86.10M) | ($100.41M) | ($118.11M) | $193.61M | ($50.25M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.05M) | ($0.91M) | ($1.22M) | ($1.21M) | ($3.31M) |
| Purchases of Investments | ($131.25M) | ($261.47M) | ($73.90M) | ($409.35M) | ($99.98M) |
| Sales of Investments | $243.34M | $232.47M | $219.57M | $166.23M | $139.47M |
| Net Cash from Investing | $112.04M | ($29.90M) | $144.45M | ($244.32M) | $36.17M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | ($21.20M) |
| Net Cash from Financing | $1.02M | $105.43M | $1.78M | $1.76M | $22.42M |
| Free Cash Flow | |||||
| Free Cash Flow | ($86.15M) | ($101.31M) | ($119.33M) | $192.40M | ($53.56M) |
| FCF Margin %(computed) | -278.72% | -448.24% | -349.38% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Foghorn Therapeutics Inc. data
About Foghorn Therapeutics Inc. (FHTX) Cash Flow Statement
Foghorn Therapeutics Inc. generated operating cash flow of ($0.09B) and free cash flow of ($0.09B) for 2025 — a FCF margin of -278.72%. Capital expenditure was ($0.00B).
Frequently asked questions
FHTX · 4 questionsFoghorn Therapeutics Inc. generated free cash flow of ($0.09B) for 2025, up 15.0% year-over-year.
FHTX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10